Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Intellia Therapeutics (NASDAQ:NTLA) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 9:00 a.m. PT. A live webcast will be available on the company’s Events and Presentations page in the Investors & Media section at www.intelliatx.com. A replay of the webcast will be available on the website for approximately 30 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – NTLA
In the Jan 7 session, NTLA gained 4.11%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.2% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.5x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 02 | Inducement grants | Neutral | +1.7% | Announcement of 22,800 RSU inducement grants for two new employees. |
| Dec 05 | Inducement grants | Neutral | -1.8% | Equity awards totaling 12,600 RSUs to three new employees under inducement plan. |
| Nov 10 | Clinical data update | Positive | +2.2% | Longer-term Phase 1 data for nex-z in ATTR cardiomyopathy showing durable TTR reduction. |
| Nov 08 | Clinical data update | Positive | +2.2% | Pooled Phase 1/2 HAE data for lonvo-z with high attack-free and LTP-free rates. |
| Nov 06 | Earnings and pipeline | Negative | -9.2% | Q3 2025 loss and disclosure of FDA clinical hold on Phase 3 MAGNITUDE trials. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news-driven moves have generally aligned with the tone of the announcements, with positive clinical data and negative regulatory/earnings items prompting correspondingly positive or negative price reactions.
Over the last few months, Intellia has balanced significant clinical progress with regulatory and financial pressures. Positive Phase 1 and pooled Phase 1/2 data for nexiguran ziclumeran and lonvoguran ziclumeran in late 2025 coincided with modest share gains. However, the FDA clinical hold on the Phase 3 MAGNITUDE programs and Q3 2025 results, including a net loss of $101.3M, led to a sharper decline. Routine inducement grant announcements around December 2025 and January 2026 saw limited price impact. Today’s J.P. Morgan conference appearance fits into this sequence as an investor-relations and visibility event rather than a clear clinical or financial inflection.
Key Terms
CRISPR medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 9:00 a.m. PT.
A live webcast will be available on the Events and Presentations page in the Investors & Media section of Intellia’s website, www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for approximately 30 days.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com
Media:
Matt Crenson
Ten Bridge Communications
media@intelliatx.com
mcrenson@tenbridgecommunications.com
